MDT

98.76

+2.13%↑

145.85

-1.34%↓

VEEV

219.49

-1.71%↓

HQY

87.3

+1.61%↑

NEOG

9.53

+3.36%↑

MDT

98.76

+2.13%↑

145.85

-1.34%↓

VEEV

219.49

-1.71%↓

HQY

87.3

+1.61%↑

NEOG

9.53

+3.36%↑

MDT

98.76

+2.13%↑

145.85

-1.34%↓

VEEV

219.49

-1.71%↓

HQY

87.3

+1.61%↑

NEOG

9.53

+3.36%↑

MDT

98.76

+2.13%↑

145.85

-1.34%↓

VEEV

219.49

-1.71%↓

HQY

87.3

+1.61%↑

NEOG

9.53

+3.36%↑

MDT

98.76

+2.13%↑

145.85

-1.34%↓

VEEV

219.49

-1.71%↓

HQY

87.3

+1.61%↑

NEOG

9.53

+3.36%↑

Inicio・Lista de Acciones・Lisata Therapeutics

L
Lisata Therapeutics

Abierto

2.11 1.93

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

2.03

Máximo

2.12

Métricas clave
By Trading Economics
Empleados	26

Dividendos
By Dow Jones
Próximas Ganancias	26 feb 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	-4.6M 16M
Apertura anterior	0.18
Cierre anterior	2.11

Lisata Therapeutics Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

14 ene 2026, 22:41 UTC

Adquisiciones, fusiones, absorciones

Canadian Natural Resources, Tourmaline File Deal Notice With Antitrust Regulator

15 ene 2026, 00:00 UTC

Ganancias

Welcome to Greenland, an Economy Reliant on Subsidies and Shrimp -- WSJ

14 ene 2026, 23:47 UTC

Charlas de Mercado

Oil Slips After Trump Appears to Tilt Away From Military Action in Iran -- Market Talk

14 ene 2026, 23:44 UTC

Charlas de Mercado

Nikkei May Decline After Hitting Record Highs; Election in Focus -- Market Talk

14 ene 2026, 23:39 UTC

Charlas de Mercado

ANZ's New Bull Still Sees Valuation Gap to Peers -- Market Talk

14 ene 2026, 23:32 UTC

Charlas de Mercado

Gold Declines on Likely Technical Correction, Possible Profit-Taking -- Market Talk

14 ene 2026, 22:56 UTC

Adquisiciones, fusiones, absorciones

Soho House Amends Rollover and Support Agreements With Broad Street Principal Investments and Others

14 ene 2026, 22:53 UTC

Adquisiciones, fusiones, absorciones

Soho House: Apollo Global Management and Goldman Sachs Asset Management Amend Debt Commitment

14 ene 2026, 22:17 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

14 ene 2026, 22:17 UTC

Charlas de Mercado

WiseTech's Revenue Growth Drivers Attract Scrutiny -- Market Talk

14 ene 2026, 22:09 UTC

Ganancias

CITIC Securities: Uptrend in China Capital Markets Supported Results >600030.SH

14 ene 2026, 22:08 UTC

Ganancias

CITIC Securities 2025 Oper Rev CNY74.83B Vs. CNY58.12B >600030.SH

14 ene 2026, 22:08 UTC

Ganancias

CITIC Securities 2025 Net CNY30.05B Vs. Net CNY21.57B >600030.SH

14 ene 2026, 21:53 UTC

Adquisiciones, fusiones, absorciones

WuXi XDC Expects 2025 Net to Increase Over 38% on Year

14 ene 2026, 21:53 UTC

Adquisiciones, fusiones, absorciones

WuXi XDC Expects 2025 Revenue to Increase More Than 45% on Year

14 ene 2026, 21:52 UTC

Adquisiciones, fusiones, absorciones

WuXi XDC Announces Positive Profit Alert for 2025

14 ene 2026, 21:51 UTC

Adquisiciones, fusiones, absorciones

Citigroup Acting as Financial Advisor to WuXi XDC

14 ene 2026, 21:51 UTC

Adquisiciones, fusiones, absorciones

WuXi XDC: Aims to Keep Listing Status of BioDlink

14 ene 2026, 21:51 UTC

Adquisiciones, fusiones, absorciones

WuXi XDC: Company to Finance BioDlink Shares Acquisition via Internal Resources

14 ene 2026, 21:50 UTC

Charlas de Mercado

Ganancias

Financial Services Roundup: Market Talk

14 ene 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

14 ene 2026, 21:49 UTC

Adquisiciones, fusiones, absorciones

WuXi XDC: BioDlink Offer to Cost HK$2.79B

14 ene 2026, 21:48 UTC

Adquisiciones, fusiones, absorciones

WuXi XDC Offers to Pay HK$4.00 for Each BioDlink International Share

14 ene 2026, 21:48 UTC

Adquisiciones, fusiones, absorciones

WuXi XDC Makes Cash Offer for BioDlink International

14 ene 2026, 21:13 UTC

Charlas de Mercado

Oil Retreats Late After Trump Comments on Iran -- Market Talk

14 ene 2026, 20:30 UTC

Charlas de Mercado

Ganancias

Danaher's Preliminary 4Q Seen as Promising -- Market Talk

14 ene 2026, 20:13 UTC

Charlas de Mercado

U.S. Natural Gas Futures Sink Ahead of Storage Report -- Market Talk

14 ene 2026, 20:08 UTC

Charlas de Mercado

Oil Futures Extend Rally on Iran Tensions -- Market Talk

14 ene 2026, 19:33 UTC

Charlas de Mercado

Nutrien Seen as Winner in Tighter 2026 Potash Market, Higher Prices -- Market Talk

14 ene 2026, 19:06 UTC

Charlas de Mercado

Ganancias

Wells Fargo Says Customers, Economy Remain Resilient -- Market Talk

Comparación entre iguales

Cambio de precio

Lisata Therapeutics Esperado

Consenso

By TipRanks

0 ratings

Comprar

Mantener

Vender

De acuerdo con 0 analistas que ofrecen calificaciones bursátiles a para Lisata Therapeutics Dist en los últimos 3 meses.

Finanzas

Acerca de Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.